{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T14:22:51Z","timestamp":1774794171035,"version":"3.50.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>In patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels \u2265 6ng\/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death. In case of suPAR testing unavailability, the Severe COvid Prediction Estimate (SCOPE) score may be used as an alternative in guiding treatment decisions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a monocenter, retrospective cohort study, including patients with SARS-CoV2 infection and respiratory failure. Patients treated with anakinra (anakinra group, AG) were compared to two control groups of patients who did not receive anakinra, respectively with \u2265 6 ng\/mL (CG1) and &lt; 6 ng\/mL (CG2) baseline suPAR levels. Controls were manually paired by age, sex, date of admission and vaccination status and, for patients with high baseline suPAR, propensity score weighting for receiving anakinra was applied. Primary endpoint of the study was disease progression at day 14 from admission, as defined by patient distribution on a simplified version of the 11-point World Health Organization Clinical Progression Scale (WHO-CPS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Between July, 2021 and January, 2022, 153 patients were included, among which 56 were treated with off-label anakinra, 49 retrospectively fulfilled prescriptive criteria for anakinra and were assigned to CG1, and 48 presented with suPAR levels &lt; 6ng\/mL and were assigned to CG2. At day 14, when comparing to CG1, patients who received anakinra had significantly reduced odds of progressing towards worse clinical outcome both in ordinal regression analysis (OR 0.25, 95% CI 0.11\u20130.54, p&lt;0.001) and in propensity-adjusted multiple logistic regression analysis (OR 0.32, 95% CI 0.12\u20130.82, p = 0.021) thus controlling for a wide number of covariates. Sensitivities of baseline suPAR and SCOPE score in predicting progression towards severe disease or death at day 14 were similar (83% vs 100%, p = 0.59).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This real-word, retrospective cohort study confirmed the safety and the efficacy of suPAR-guided, early use of anakinra in hospitalized COVID-19 patients with respiratory failure.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0273202","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T17:45:55Z","timestamp":1680630355000},"page":"e0273202","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5276-2603","authenticated-orcid":true,"given":"Francesco Vladimiro","family":"Segala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2273-0683","authenticated-orcid":true,"given":"Emanuele","family":"Rando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7734-0538","authenticated-orcid":true,"given":"Marcantonio","family":"Negri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Catania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Sanmartin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Murri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":true,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Fantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"pone.0273202.ref001","unstructured":"WHO Coronavirus (COVID-19) Dashboard. [cited 13 Apr 2022]. Available: https:\/\/covid19.who.int"},{"key":"pone.0273202.ref002","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020\u201321","volume":"0","author":"H Wang","year":"2022","journal-title":"The Lancet"},{"key":"pone.0273202.ref003","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.","volume":"323","author":"Z Wu","year":"2020","journal-title":"JAMA"},{"key":"pone.0273202.ref004","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity","volume":"9","author":"MF Osuchowski","year":"2021","journal-title":"Lancet Respir Med"},{"key":"pone.0273202.ref005","first-page":"1","article-title":"IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19.","author":"G Renieris","year":"2022","journal-title":"J Innate Immun."},{"key":"pone.0273202.ref006","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment","volume":"97","author":"A. Parasher","year":"2021","journal-title":"Postgrad Med J"},{"key":"pone.0273202.ref007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13054-020-02897-4","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.","volume":"24","author":"N Rovina","year":"2020","journal-title":"Crit Care."},{"key":"pone.0273202.ref008","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19.","volume":"10","author":"E Kyriazopoulou","year":"2021","journal-title":"eLife"},{"key":"pone.0273202.ref009","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"E Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"pone.0273202.ref010","article-title":"Development and validation of SCOPE score: a clinical score to predict progression of COVID-19 pneumonia to severe respiratory failure.","author":"EJ Giamarellos-Bourboulis","year":"2022","journal-title":"Cell Rep Med."},{"key":"pone.0273202.ref011","article-title":"EMA recommends approval for use of Kineret in adults with COVID-19.","author":"EMA","year":"2021","journal-title":"European Medicines Agency"},{"key":"pone.0273202.ref012","year":"2022","journal-title":"Clinical Guidance for COVID-19 Vaccination | CDC"},{"key":"pone.0273202.ref013","article-title":"COVID-19 Vaccination","author":"CDC","year":"2020","journal-title":"Centers for Disease Control and Prevention"},{"key":"pone.0273202.ref014","article-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.","author":"NIH","journal-title":"National Institutes of Health. In: COVID-19 Treatment Guidelines"},{"key":"pone.0273202.ref015","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"JC Marshall","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"pone.0273202.ref016","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"pone.0273202.ref017","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"A Sheikh","year":"2021","journal-title":"The Lancet"},{"key":"pone.0273202.ref018","author":"SARS-COV-2 Delta variant now dominant in much of the European Region and efforts must be reinforced to prevent transmission, warn WHO\/Europe and ECDC","year":"2021","journal-title":"European Centre for Disease Prevention and Control"},{"key":"pone.0273202.ref019","author":"Assessment of the further spread and potential impact of the SARS-CoV-2 Omicron variant of concern in the EU\/EEA, 19th update","year":"2022","journal-title":"European Centre for Disease Prevention and Control"},{"key":"pone.0273202.ref020","article-title":"suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial.","author":"Hellenic Institute for the Study of Sepsis","year":"2021","journal-title":"clinicaltrials.gov"},{"key":"pone.0273202.ref021","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.","volume":"9","author":"CORIMUNO-19 Collaborative group","year":"2021","journal-title":"Lancet Respir Med"},{"key":"pone.0273202.ref022","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.","volume":"9","author":"J Declercq","year":"2021","journal-title":"Lancet Respir Med."},{"key":"pone.0273202.ref023","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"G Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"pone.0273202.ref024","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/S2665-9913(21)00012-6","article-title":"Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study","volume":"3","author":"G Cavalli","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"pone.0273202.ref025","first-page":"CD015308","article-title":"Interleukin-1 blocking agents for treating COVID-19.","volume":"1","author":"M Davidson","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"key":"pone.0273202.ref026","unstructured":"Interleukin-1 Inhibitors. In: COVID-19 Treatment Guidelines [Internet]. [cited 5 Apr 2022]. Available: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/immunomodulators\/interleukin-1-inhibitors\/"},{"key":"pone.0273202.ref027","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"S. Suissa","year":"2008","journal-title":"Am J Epidemiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T17:46:23Z","timestamp":1680630383000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273202"}},"subtitle":[],"editor":[{"given":"Cecilia","family":"Acuti Martellucci","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273202","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}